Abstract
Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Current Pharmaceutical Design
Title:Stimuli-Responsive Nanoparticles for siRNA Delivery
Volume: 21 Issue: 29
Author(s): Josimar O. Eloy, Raquel Petrilli, Renata F. V. Lopez and Robert J. Lee
Affiliation:
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Abstract: Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Export Options
About this article
Cite this article as:
Eloy O. Josimar, Petrilli Raquel, Lopez F. V. Renata and Lee J. Robert, Stimuli-Responsive Nanoparticles for siRNA Delivery, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901095349
DOI https://dx.doi.org/10.2174/1381612821666150901095349 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategies for Papillary Microcarcinoma of the Thyroid
Current Cancer Therapy Reviews Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines
Current Medicinal Chemistry Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry The Role of Endocervical Curettage in Satisfactory Colposcopy
Current Women`s Health Reviews Sex Steroid Hormone Effects in Normal and Pathologic Conditions in Lung Physiology
Mini-Reviews in Medicinal Chemistry The Impact of HAART on HPV-Related Cervical Disease
Current HIV Research MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design The Screening of Renoprotective Agents by 99mTc-DMSA: A Review of Preclinical Studies
Current Radiopharmaceuticals Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Nanomedical Applications of Amphiphilic Dendrimeric Micelles
Current Medicinal Chemistry